Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study

Giovanni Tarantino, MD¹, Domenico Capone, MD², Paola Contaldi, MD¹, Adriana Gianno, MD¹, Mosca Teresa, BLT², and Antonella Tufano, MD, PhD¹

Abstract
Warfarin is an oral anticoagulant, commonly used for primary and secondary prevention of venous and arterial thromboembolic events. The drug is characterized by narrow therapeutic index, widespread individual variability in clinical response, and high rates of adverse events, particularly bleeding complications. For these reasons, a close monitoring of the dosage, using the frequent assessment of coagulation status by means of International Normalized Ratio value, is mandatory. Warfarin is metabolized by hepatic cytochrome P-450. High CYP 450 activity may lead to low drug concentration and requires high warfarin doses to reach efficacy; conversely, low CYP 450 activity is responsible for high drug concentration and needs for low doses to avoid potential toxicity risks. The major isoforms of CYP involved in the metabolism of warfarin sodium are CYP1A2 (for the R-warfarin) and CYP2C9 (for the S-warfarin). The probes for testing CYP1A2 are phenacetin and caffeine while for CYP2C9 tolbutamide. Although S-warfarin has major activity, it was decided to exclude its phenotyping for ethical issues, being mandatory to use a drug (tolbutamide). Instead, it was chosen to test the 1A2 isoform, as the activity of the latter isoform could be investigated by using caffeine contained in the caffeinated beverages. Specifically, a single-point concentration of salivary caffeine (total overnight salivary caffeine assessment [TOSCA]) after an overnight period of the caffeinated beverages abstinence was utilized. In the present study, 75 nonsmoker patients regularly receiving warfarin sodium were enrolled. The results have showed a significant association of the warfarin dose with TOSCA values (coefficient \(= -0.15\), standard error \(= 0.04\), 95% confidence interval \(= -0.24\) to \(-0.06\), \(t = -3.23, P = .002\)). In conclusion, the phenotyping of CYP1A2 by TOSCA could be useful, if further proven, to help manage patients on warfarin in order to lessen severe adverse events.

Keywords
phenotyping, CYP 4501A2, TOSCA, warfarin

Introduction
Vitamin K antagonists (VKAs) are commonly used for primary and secondary prevention of venous and arterial thromboembolic events. Warfarin sodium is the most widely prescribed VKA. The chemical name of warfarin sodium is 3-(\(\alpha\)-acetonylbenzyl)-4-hydroxycoumarin sodium salt, which is a racemic mixture of the R- and S-enantiomers.¹ In humans, the R-enantiomer exhibits an estimated eudismic potency ratio approximately 3.4 times less than of S-enantiomer, but its contribution for action may be important.²

Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the natural anticoagulant proteins C and S.³⁵ Approximately 99% of the drug is bound to plasma proteins.⁶ Warfarin is metabolized by hepatic cytochrome P-450.⁷ The half-life of racemic warfarin ranges from 36 hours to 42 hours.⁸

¹ Department of Clinical Medicine and Surgery, “Federico II” University, Naples, Italy
² Integrated Care Department of Clinical Neurosciences, Anesthesiology and Drug-Use, Section of Clinical Pharmacology, “Federico II” University, Naples, Italy

Corresponding Author:
Giovanni Tarantino, Department of Clinical Medicine and Surgery, “Federico II” University, Naples, Italy.
Email: tarantin@unina.it

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
with the mean half-life of 51.1 hours for R-warfarin and 33.1 hours for S-warfarin. Thus, the clearance of R-warfarin is lower than that of S-warfarin.\(^9\)

Adverse events of warfarin therapy include bleeding episodes involving in particular, the gastrointestinal (GI) and urinary tract and the risk of cerebral hemorrhage is the most fearsome complication in particular in elderly patients.\(^{10,11}\)

As known, the relationship between the dose of warfarin and the response is modified by genetic and environmental factors (diet and drugs) that can influence the absorption, pharmacokinetics, and pharmacodynamics. It is difficult to reach a stable therapeutic effect of warfarin sodium and for this reason, it is recommended a close monitoring of the dosage, by using the frequent assessment of coagulation status.\(^{12}\) In a large population, the recommended maintenance warfarin dose is from 2.5 mg/day to 10 mg/day with a maximum to 15 mg/day; however, the effective daily dose varies from 0.5 mg to 60 mg from patient to patient.\(^{13,14}\)

Consequently, it could be important evaluating the phenotype of CYP 450 activity to obtain an optimal dose regimen. In fact, high CYP 450 activity leads to low drug concentration and requires high warfarin doses to reach drug efficacy; conversely, low CYP 450 activity is responsible for high drug concentration and needs for low doses to avoid potential toxicity risks.\(^{15}\) Therefore, it could be advisable to foresee the metabolic pattern of the treated patients for avoiding both the events.

It is well known that the warfarin metabolism can be influenced by several factors comprising race, gender, age, diet, and concomitant drugs. Thus, the evaluation of metabolic pattern is recommended and useful to better foresee the potential bleeding risk in these patients. The major isoforms of CYP involved in the metabolism of warfarin sodium are CYP1A2 (for the R-warfarin) and CYP2C9 (for the S-warfarin).\(^{7,16}\) The probes for testing CYP1A2 are phenacetin\(^ {17}\) and caffeine,\(^ {18}\) while for CYP2C9 the probe for testing is tolbutamide.\(^ {19}\)

Although S-warfarin has major activity, it was decided to exclude its phenotyping for ethical issues, being mandatory to use a drug (tolbutamide). The choice of phenotyping CYP1A2 activity fell upon testing R-warfarin. Concerning the latter enantiomer, 2 options were available: phenacetin and caffeine. As phenacetin showed the same ethical limitations of tolbutamide, the caffeine option was obliged because coffee is a usual beverage of our population. That said, owing to the minor power of probe of caffeine compared to that of phenacetin,\(^ {20}\) it was necessary that the patients assumed a satisfactory intake of coffee for a reliable assessment of metabolic profile. On the basis of recent evidence, no difference should be attributed to the type of probe chosen as it has been clearly demonstrated that the metabolic profiles are similar (within the 20%), except for CYP2A6, not involved in the warfarin metabolism and 3A4.\(^ {15}\) Finally, the isof orm CYP3A4 is responsible for high incidence of drug–drug interactions with consequent source of pharmacokinetic bias.\(^ {7}\)

In this research, total overnight salivary caffeine assessment (TOSCA) was used for phenotyping the CYP1A2 activity. Total overnight salivary caffeine assessment was determined by means a single-point concentration of salivary caffeine after an overnight period of the caffeinated beverages abstinence. The pharmacokinetic and analytical strengths of the test were extensively validated in a previous study.\(^ {21}\)

The aim of this research was to investigate any relationship between the dose of warfarin sodium and the CYP1A2 activity, evaluated by TOSCA, in patients on warfarin treatment in order to likely reduce inefficacy or bleeding risk.

### Patients and Methods

Seventy-five nonsmoker patients on current treatment with warfarin sodium were included in this observational study. Patients were enrolled from April 2015 to February 2016 at the outpatient clinic of the Department of Clinical Medicine and Surgery, "Federico II" University, Naples, Italy.

In Table 1, age of the enrolled patients and information concerning diseases for which they were on anticoagulant therapy were reported. In Table 2, warfarin dose and cotherapies were described. The warfarin dose considered for each patient was that allowing to maintain the international normalized ratio (INR) value in the stable recommended range of 2 to 3 confirmed by repeated measurements.\(^ {22}\)

Total overnight salivary caffeine assessment was performed at this steady-state condition (INR within therapeutic range for at least 4 weeks). Patients were advised not to assume drugs and/or food able to interfere with the investigated metabolic pathway at least 2 weeks before performing TOSCA test in order to avoid any potential pharmacokinetic interactions. In particular, among the inhibitors, fluvoxamine, quinolones, and grapefruit juice were excluded; and among the inducers, omeprazole, phenobarbital, rifampicin, Hypericum perforatum, and Brussels sprouts were excluded. In addition, patients with impaired laboratory liver tests were kept out from the study.

As a previous study has fixed mean caffeine intake from caffeinated beverages at 3.02 mg/kg\(^ {23}\) and taking into account that the content of caffeine in typical Italian caffeinated coffee is almost 50 mg/cup,\(^ {24}\) patients were allowed to assume 2 to 4 cups of coffees per day, corresponding to 100 mg to 200 mg of caffeine, according to their usual habit.

During the day before the test, patients were allowed to consume their caffeinated beverage/food in the late afternoon (prior to 2000 hours). At 0800 hours of the following day, a sample of 2 cc of saliva was collected after a unique and short mouth rinsing and having chewed parafilm for several minutes. Saliva specimens were rough centrifuged, and the supernatant was stored frozen until analysis.

Caffeine was measured in the saliva by the enzyme-multiplied immunoassay technique (EMIT) assay from Siemens Healthcare Diagnostics Inc (Tarrytown, New York) on a CD×90 automated analyzer (Tema Ricerca, Castenaso, Italy). The analytical performance parameters of the EMIT caffeine assay were the following: the lower limit of quantitation was 0.15 mcg/mL; the intraday and interday precision were 4.0 and 3.9%, respectively; and the range of the standard curve was 0 to 30 mcg/mL.\(^ {21,25}\)
The study was carried out according to the Declaration of Helsinki and its amendments, which include written informed consent by all participants before their enrolment, and was approved by our Medical School Ethics Committee.

### Statistics

First, data of every studied variable were analyzed in order to assess the distribution, by the Shapiro-Wilk (S-W) test. Accordingly, both TOSCA values and doses were expressed as median plus 25 to 75 interquartile range (IQR), having the S-W test rejected normality ($P < .0001$ and $P = .0125$, respectively). Vice versa, age was normally distributed ($P = .29$) and was expressed as mean $\pm$ SD. The prediction of the dose of warfarin sodium by TOSCA values was estimated by linear regression (least squares method), calculating coefficient, standard error, 95% confidence interval (CI), $t$ value, and $P$. To evaluate the effect size in the regression, $R^2$ was calculated, and values of 0.01, 0.09, or 0.25 were considered small, medium, or large, respectively. In order to study the phenotype distribution of CYP1A2, its values were broken into percentiles (<25 rapid metabolizers, 25-75 intermediate metabolizers, >75 slow metabolizers). Dealing with differences of TOSCA values between more than 2 groups, the analysis of variance (ANOVA) Kruskal-Wallis with Conover test for the post hoc analysis was used.

The relationship between TOSCA values and warfarin doses in the 3 subgroups was assessed by the Spearman coefficient of rank correlation ($\rho$). $P$ value < .05 was considered significant.

---

**Table 1. Demographic Characteristics of the Patients With Related Disease.**

| Patient | Gender | Age (Years) | Diseases                      |
|---------|--------|-------------|-------------------------------|
| 1       | F      | 37          | Recurrent DVT                 |
| 2       | M      | 59          | DVT and SVT                   |
| 3       | F      | 35          | DVT, PE, CVT                  |
| 4       | M      | 44          | Prosthetic aortic valve       |
| 5       | F      | 62          | DVT and PE                    |
| 6       | F      | 48          | DVT and PE                    |
| 7       | M      | 41          | Recurrent SVT                 |
| 8       | F      | 88          | DVT                           |
| 9       | F      | 76          | DVT, SVT, and AF              |
| 10      | M      | 59          | DVT and PE                    |
| 11      | F      | 68          | DVT and PE                    |
| 12      | M      | 76          | AF                            |
| 13      | M      | 61          | DVT                           |
| 14      | F      | 25          | CVT                           |
| 15      | M      | 48          | DVT                           |
| 16      | M      | 68          | DVT                           |
| 17      | F      | 36          | DVT                           |
| 18      | F      | 31          | Portal vein thrombosis        |
| 19      | F      | 81          | Recurrent SVT and Budd-Chiari syndrome |
| 20      | F      | 79          | AF and AT                     |
| 21      | M      | 43          | Recurrent DVT                 |
| 22      | M      | 57          | DVT and PE                    |
| 23      | M      | 62          | Acute myocardial infarction and stroke, CVT |
| 24      | M      | 69          | Thrombosis of portal and mesenteric veins |
| 25      | M      | 52          | AF                            |
| 26      | M      | 58          | DVT and PE                    |
| 27      | M      | 51          | Aortic valve and SVT          |
| 28      | M      | 49          | DVT                           |
| 29      | M      | 44          | DVT and CVT                   |
| 30      | F      | 40          | CVT                           |
| 31      | M      | 55          | AT                            |
| 32      | M      | 67          | DVT                           |
| 33      | M      | 81          | AF                            |
| 34      | M      | 62          | DVT and PE                    |
| 35      | M      | 56          | DVT and AF                    |
| 36      | M      | 80          | DVT and PE                    |
| 37      | M      | 72          | Recurrent DVT                 |
| 38      | F      | 68          | SVT                           |
| 39      | M      | 67          | DVT and SVT                   |
| 40      | M      | 63          | DVT and PE                    |
| 41      | F      | 48          | DVT and PE                    |
| 42      | M      | 60          | PE                            |
| 43      | M      | 74          | DVT and PE                    |
| 44      | F      | 61          | PE                            |
| 45      | F      | 82          | PE and DVT                    |
| 46      | F      | 50          | DVT                           |
| 47      | F      | 32          | DVT                           |
| 48      | F      | 70          | SVT and DVT                   |
| 49      | M      | 70          | Recurrent TIA and recurrent SVT |
| 50      | M      | 65          | DVT                           |
| 51      | M      | 24          | DVT                           |
| 52      | M      | 44          | CVT                           |
| 53      | M      | 61          | Recurrent SVT                 |
| 54      | M      | 73          | DVT                           |

(continued)
Table 2. Warfarin Dose, TOSCA Value, CYP1A2 Phenotype, and Co-Therapy of the Patients.

| Patient | Warfarin Dose  (mg/day) | TOSCA  (mcg/mL) | CYP1A2 Phenotype | Co-Therapy                                                                 |
|---------|------------------------|----------------|-----------------|---------------------------------------------------------------------------|
| 1       | 5.89                   | 0.00           | R               | None                                                                      |
| 2       | 3.74                   | 1.57           | S               | Rosuvastatin, lisinopril, hydrochlorothiazide, lansoprazole               |
| 3       | 7.73                   | 0.00           | R               | Atorvastatin, rabeprazole                                                |
| 4       | 7.05                   | 1.23           | S               | Nifedipine, olmesartan, hydrochlorothiazide, carvedilol                  |
| 5       | 6.25                   | 0.28           | I               | Ramipril, methylprednisolone, amitriptyline, colcalficrol, ranitidine   |
| 6       | 4.76                   | 0.20           | I               | Metformin, repaglinide, ezetimibe, levothyrsoxine, ranitidine, lisinopril|
| 7       | 4.99                   | 1.98           | S               | None                                                                      |
| 8       | 0.53                   | 5.70           | S               | Pantoprazole, simvastatin, citalopram, telmisartan, hydrochlorothiazide  |
| 9       | 4.1                    | 0.40           | I               | Rabeprazole, levothyroxine, irbesartan, metformin, amiodarone, tizanidine, pravastatin, levosulpiride, tramadol |
| 10      | 5.05                   | 0.20           | I               | Rabeprazole, irbesartan, verapamil, atorvastatin, acetylsalicylic acid, clopidogrel |
| 11      | 6.69                   | 0.40           | I               | Atorvastatin, ramipril, levetiracetam, metformin, colcalficrol           |
| 12      | 1.25                   | 1.80           | S               | Digoxin, rabeprazole, hydroxychloroquine, furosemide, carvedilol, dutasteride, canrenoate |
| 13      | 9.2                    | 1.00           | S               | Quinazide, carvedilol, metformin, pravastatin                            |
| 14      | 7.3                    | 0.40           | I               | None                                                                      |
| 15      | 2.32                   | 0.20           | I               | Rabeprazole, ramiplril, prednisone, clopidogrel, amlodipine, irbesartan, atorvastatin, 5-aminosalicylic acid |
| 16      | 7.23                   | 0.20           | I               | Lansoprazole, pravastatin, allopurinol, cilazapril, hydrochlorothiazide |
| 17      | 5.71                   | 0.60           | I               | Topiramate, hydroxychloroquine, colcalficrol                             |
| 18      | 2.0                    | 0.10           | R               | Lansoprazole, leflunomide                                               |
| 19      | 5.8                    | 0.70           | I               | Losartan, pravastatin, pantoprazole, hydrochlorothiazide                 |
| 20      | 3.3                    | 0.80           | I               | Levlothyrsoxine, carvedilol, simvastatin, furosemide, digoxin, irbesartan, hydrochlorothiazide |
| 21      | 1.42                   | 0.30           | I               | None                                                                      |
| 22      | 5.71                   | 0.60           | I               | Doxazosin, levothyroxine, enalapril, hydrochlorothiazide, silodosin, dutasteride |
| 23      | 5.35                   | 0.70           | I               | Carvedilol, pravastatin, isosorbide mononitrate                           |
| 24      | 6.43                   | 0.80           | I               | Metformin, telmisartan, hydrochlorothiazide, atorvastatin, linagliptin, febuxostat, carbidopa, pramipexole |
| 25      | 1.96                   | 0.60           | I               | Metformin, pantoprazole, ezetimibe, simvastatin, amlodipine, irbesartan, hydrochlorothiazide, allopurinol, bisopropolol |
| 26      | 1.78                   | 1.30           | S               | Colecalciferol, ramipril, citalopram, rabeprazole                        |
| 27      | 3.39                   | 0.50           | I               | Carvedilol, candesartan, digoxin                                         |
| 28      | 2.46                   | 0.50           | I               | Pantoprazole, allopurinol, magaldrate, ursodeoxycholic acid              |
| 29      | 8.21                   | 0.20           | I               | Rabeprazole, carvedilol, hydroxyurea, carbamazepine                     |
| 30      | 3.75                   | 0.50           | I               | Topiramate, propranolol                                                  |
| 31      | 4.91                   | 0.10           | R               | Clopidogrel, pravastatin, ranitidine, silodosine, hydroxyurea, l-propionil carnitine, allopurinol |
| 32      | 7.85                   | 0.50           | I               | Levothyroxine, irbesartan, bisoprolol, pantoprazole                      |
| 33      | 3.83                   | 0.30           | I               | Atenolol, atorvastatin, rabeprazole                                      |
| 34      | 5.12                   | 0.50           | I               | Felodipine, ramiplril, simvastatin                                       |
| 35      | 5.71                   | 0.80           | I               | Levothyroxine, losartan, hydrochlorothiazide, flecainide, ranitidine, metoprolol, ezetimibe, colecalciferol |
| 36      | 3.57                   | 0.80           | I               | Tapazole, ramiplril, hydrochlorothiazide, atenolol, allopurinol, pravastatin |
| 37      | 2.14                   | 1.60           | S               | Rabeprazole, nebivolol, nimodipine, l-acetylcarnitine, dutasteride, ramipril, alfuozinos, metformin, rosuvastatin |
| 38      | 4.1                    | 0.70           | I               | Lansoprazole, repaglinide, allopurinol, colecalcifer, valsartan, hydrochlorothiazide |
| 39      | 4.91                   | 3.60           | S               | Irbesartan, hydroxychloroquine, dutasteride, silodosine                  |
| 40      | 2.5                    | 0.90           | S               | Allopurinol, amlodipine, fluvastatin                                     |
| 41      | 7.5                    | 0.60           | I               | None                                                                      |
| 42      | 3.9                    | 0.30           | I               | Levothyroxine, pantoprazole, sildenafil, amiloride/hydrochlorothiazide, irbesartan, dambrisant, flecainide |
| 43      | 5.0                    | 0.60           | I               | Levothyroxine, rabeprazole, telmisartan, simvastatin, alfuozinos         |
| 44      | 3.75                   | 0.80           | I               | Pantoprazole, pravastatin, denosumab, abatacept, N-acetylcysteine         |
| 45      | 1.6                    | 3.80           | S               | Pantoprazole, carvedilod, furosemide, allopurinol, atorvastatin, digoxin, amlodipine, calcitriol, memantine |
| 46      | 5.89                   | 0.40           | I               | Simvastatin, ezetimibe, pantoprazole, levothyroxine, nebivolol           |
| 47      | 9.28                   | 0.00           | R               | Hydroxychloroquine, methylprednisolone, colecalcifer, lansoprazole      |
| 48      | 5.0                    | 1.50           | S               | Ezetimibe                                                                 |
| 49      | 4.2                    | 0.20           | I               | Rabeprazole, colchicine, prednisone, colecalcifer, telmisartan, amlodipine, simvastatin, tamsulosin, dutasteride |

(continued)
Results

The age of our patients, 43 males and 32 females, was 57.9 ± 15.0 years.

The median values of TOSCA and dose were 0.50 mcg/mL (IQR = 0.20-0.80) and 5.0 mg/day (IQR = 3.6-6.6), respectively. Figure 1 shows a significant association between the warfarin dose and TOSCA value (coefficient = −0.15, standard error = 0.04, 95% CI = −0.24 to −0.06, t = −3.23, P = .002 and $R^2 = 0.12$).

The cutoff of TOSCA values classifying rapid, intermediate, and slow metabolizers were <0.22, 0.22 to 0.80, and >0.80, respectively. The phenotype distribution of CYP1A2 in our population was 19 rapid metabolizers (25.3%), 38 intermediate metabolizers (50.7%), 18 slow metabolizers (24.0%; Table 2 and Figure 2). The medians (IQRs) of the 3 groups, that is, rapid, intermediate, and slow metabolizers, were different one

Table 2. (continued)

| Patient | Warfarin Dose (mg/day) | TOSCA (mcg/mL) | CYP1A2 Phenotype | Co-Therapy |
|---------|------------------------|----------------|-----------------|------------|
| 50      | 6.25                   | 0.00           | R               | Ramipril, ursodeoxycholic acid |
| 51      | 3.03                   | 0.20           | I               | None       |
| 52      | 7.5                    | 0.60           | I               | Ezetimibe, rosuvastatin, levothyroxine, lansoprazole |
| 53      | 10.0                   | 0.20           | I               | Simvastatin, allopurinol |
| 54      | 1.96                   | 0.40           | I               | Ramipril, finasteride, silodosine |
| 55      | 2.14                   | 0.00           | R               | Levothyroxine, losartan, hydrochlorothiazide, metoprolol |
| 56      | 6.44                   | 1.30           | S               | Pantoprazole, atorvastatin, bisopropiol, perindopril, febuxostat |
| 57      | 3.75                   | 1.50           | S               | Lansoprazole, ramipril, amloidipine, tamulosin |
| 58      | 6.96                   | 0.00           | R               | Clopidogrel, rabeprazole, atorvastatin, topiramate |
| 59      | 5.17                   | 0.40           | I               | Carvedilol, atorvastatin |
| 60      | 7.14                   | 0.10           | R               | Pantoprazole, ramipril, amloidipine, clonidogrel, atorvastatin cilostazol |
| 61      | 10.0                   | 0.20           | I               | Hydroxychloroquine, calcifediol, pantoprazole |
| 62      | 4.64                   | 1.10           | S               | Flecainide, bisopropiol, valsartan, pantoprazole |
| 63      | 2.5                    | 4.60           | S               | Simvastatin, ramipril |
| 64      | 6.6                    | 0.70           | I               | Irbesartan, hydrochlorothiazide, ranitidine |
| 65      | 4.73                   | 0.30           | I               | None       |
| 66      | 6.07                   | 0.30           | I               | None       |
| 67      | 5.0                    | 0.60           | I               | Atorvastatin |
| 68      | 15.0                   | 1.30           | S               | Acetazolamide, topiramate, flunarizine, rabeprazole |
| 69      | 5.7                    | 0.70           | I               | Lovastatin, atenolol, levothyroxine, olmesarten, amloidipine, ranitidine |
| 70      | 4.28                   | 0.50           | I               | Pravastatin, candesarten, bisopropiol |
| 71      | 6.78                   | 0.80           | I               | None       |
| 72      | 0.86                   | 3.40           | S               | None       |
| 73      | 9.64                   | 0.20           | I               | None       |
| 74      | 5.89                   | 0.30           | I               | Irbesartan |
| 75      | 3.75                   | 0.60           | I               | Levothyroxine, simvastatin, silodosine |

Abbreviations: I, intermediate metabolizer; R, rapid metabolizer; S, slow metabolizer; TOSCA, total overnight salivary caffeine assessment.

Figure 1. Correlation between warfarin dose and TOSCA value (thick, continuous, and dotted lines represent regression, 95% prediction, and 95% confidence intervals, respectively), linear regression (least squares method). TOSCA indicates total overnight salivary caffeine assessment.

Figure 2. Distribution of the 3 phenotypes (metabolizers) showing no overlap using ANOVA Kruskal-Wallis. ANOVA indicates analysis of variance; I, intermediate; R, rapid; S, slow.

warfarin dose and TOSCA value (coefficient = −0.15, standard error = 0.04, 95% CI = −0.24 to −0.06, t = −3.23, P = .002 and $R^2 = 0.12$).

The cutoff of TOSCA values classifying rapid, intermediate, and slow metabolizers were <0.22, 0.22 to 0.80, and >0.80, respectively. The phenotype distribution of CYP1A2 in our population was 19 rapid metabolizers (25.3%), 38 intermediate metabolizers (50.7%), 18 slow metabolizers (24.0%; Table 2 and Figure 2). The medians (IQRs) of the 3 groups, that is, rapid, intermediate, and slow metabolizers, were different one
from the other: 0.20 (0.0–0.20), 0.55 (0.40–0.70), and 1.53 (1.23–3.58), respectively, \( P \leq .001 \).

Among subgroups, corresponding to phenotypes, slow metabolizers showed a strong correlation between TOSCA values and warfarin doses, \( \rho = -0.57 \) (\( P = .008 \)).

**Discussion**

Although widely used for the prevention and treatment of thromboembolic diseases, warfarin is well noted for its narrow therapeutic index, large individual variability in clinical response, high rates of adverse events, and sometimes serious and frequent adjustment of therapeutic dose for each patient. Furthermore, polymorphisms of enzymatic isoforms involved in warfarin metabolism have been shown to be important in determining individual variability in patients on warfarin therapy. From this perspective, warfarin treatment is considered well suited as a model for studying individualized medicine.26 As previously emphasized, frequent monitoring of the patient during warfarin therapy is commonly performed by the INR value. Currently, the INR represents a simple and relatively economical tool for clinicians to individualize warfarin dose, which is related to different metabolic profiles. The time required to reach the therapeutic INR range may differ significantly among patients, from days to months.

For all isoforms of CYP 450 have been generally identified 3 phenotypes of metabolism extent: slow, intermediate, and rapid metabolizers although ethnic differences have been observed.15 Specifically, the distribution of CYP1A2 was confirmed in patients from Italy, China, and a State of the United States (Arkansas) with percentages of slow, intermediate, and rapid ranging 12 to 13, 51 to 67, and 20 to 37, respectively.27 This trimodal distribution of the CYP1A2 activity was confirmed in our population.

Several approaches have been performed for CYP1A2 phenotyping. A previous research has measured caffeine metabolites in a spot urine sample collected after 4 hours to 5 hours of coffee consumption by using the high-performance liquid chromatography (HPLC) assay considered more complex than EMIT.28 Data of the literature confirmed a strong correlation coefficient (0.97) for HPLC versus EMIT caffeine assay.29 Similarly, in another study, the saliva was collected 5 hours to 7 hours after a “drug” administration (caffeine), by using the \(^{13}\text{C}\)-caffeine breath test requiring 5 determinations of breath samples (before and at 15, 30, 45, and 60 minutes after caffeine ingestion).30 Total overnight salivary caffeine assessment is fast, economic, and requires one sampling point for CYP1A2 phenotyping. It utilizes coffee and “no drug”; and the matrix is saliva, which is simple to collect. On the basis of these characteristics, the test is easy to perform.

While all data showed an evident inverse correlation between TOSCA values and warfarin doses confirming a potential role of CYP1A2 phenotyping for a more accurate evaluation of warfarin response, the separate evaluation in the 3 subgroups of phenotypes confirmed the negative relationship for slow metabolizers. This aspect is not of secondary importance as in the warfarin treatment, the issue of the drug-related complications (ie, GI bleeding) is crucial. Vice versa, regarding the lack of statistical significance between TOSCA values and warfarin doses in the other 2 groups, the narrow range of dispersion of TOSCA values could be a likely explanation. Despite the introduction of direct oral anticoagulant drugs (DOACs), warfarin treatment remains useful for several indications (mechanical valve replacement, severe thrombophilic conditions), and it has been reported that interruption/discontinuation of warfarin therapy increases the risk of thromboembolism.31

Moreover, in the metabolism of DOACs, both CYP 450 system (by several isoforms) and P-glycoprotein are involved, except for dabigatran using only P-glycoprotein, and therefore potential drug–drug interactions can be expected.32 In addition, in some clinical occasion, it could be necessary to switch patients from DOACs to warfarin therapy and the management of these anticoagulants when transitioning from or back to warfarin, or to low-molecular-weight heparin around surgery or in case of major hemorrhage, requires knowledge of their pharmacokinetics and mechanism of action.33

Multiple clinical factors for determining optimal warfarin dosage, namely age, weight, and use of interacting co-medications, although reported in Tables 1 and 2, were not statistically evaluated due to the suggested poor clinical burden. In fact, realistically, it would not be possible to evaluate each of the clinical factors in trials to optimize warfarin dosing.34

This study is characterized by the following potential drawbacks: (i) the reduced number of enrolled patients taking into account the well-known wide pharmacokinetic variability of warfarin, but this research is a pilot study; (ii) the lack of the CYP1A2 genotyping, burdened by invasiveness, difficulty of the analytical tool, and high costs; moreover, a previous study highlighted the importance of pharmacogenetic research of CYP1A2 concerns smokers and thus it does not seem to be appropriate to our population.35

As previously emphasized, the clinical utility of the CYP1A2 phenotyping by a simple, reliable, noninvasive test such as TOSCA, if confirmed in large-scale studies enrolling patients from different ethnicity, alimentary habit, and life style, could be used to help the clinical management of patients on warfarin treatment.

**Authors’ Note**

GT conceived the study, participated in research design, in performing statistics, and in writing the paper. DC participated in research design and the analytical tools, in performing statistics, and in writing the paper. PC and AG participated in collecting clinical and laboratory data. TM participated in the analytical tools. AT participated in collecting data.

**Acknowledgment**

We are deeply grateful to Professor G. Di Minno for helping us with his expertise.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Breckenridge AM. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol. 1978;15(1):19-26.
2. Maddison J, Somogyi AA, Jensen BP, James HM, Gentgall M, Rolan PE. The pharmacokinetics and pharmacoodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. Br J Clin Pharmacol. 2013;75(1):208-216.
3. Whitlon DS, Sadowski JA, Suttie JW. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371-1377.
4. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem. 1982;257(19):11210-11212.
5. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol. 1988;25(1):1-7.
6. Hirsch J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114(suppl 5):445S-469S.
7. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
8. O’Reilly RA. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, eds. The New Dimensions of Warfarin Prophylaxis. Vol. 214. New York, NY: Advances in experimental medicine and biology Plenum; 1986:205-212.
9. O’Reilly RA. Studies on the optical enantiomers of warfarin in man. Clin Pharmacol Ther. 1974;16(2):348-354.
10. Agno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e44S-e88S.
11. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-1441.
12. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin. 2008;26(2):157-167.
13. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45(8):704-706.
14. Hallak HO, Wedlun PJ, Modi MW, Lewis GL, Woodruff B, Trowbridge AA. High clearance of (S)-warfarin resistant subject. Br J Clin Pharmacol. 1993;35(3):327-330.
15. Spaggiari D, Geiser L, Daiz Y, Rudaz S. Phenotyping of CYP450 in human liver microsomes using the cocktail approach. Anal Bioanal Chem. 2014;406(20):4875-4887.
16. Spaggiari D, Geiser L, Daiz Y, Rudaz S. A cocktail approach for assessing the in vitro activity of human cytochrome CYP450s: an overview of current methodologies. J Pharm Biomed Anal. 2014;101:221-237.
17. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998;87(12):1502-1507.
18. Tassaneeyakul W, Mohamed Z, Birkett DJ, et al. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics. 1992;2(4):173-183.
19. Edwards RJ. Targeting antipeptide antibodies towards cytochrome P450 enzymes. Methods Mol Biol. 1998;107:239-249.
20. Grant DM, Campbell ME, Tang BK, Kalow W. Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. Biochem Pharmacol. 1987;36(8):1251-1260.
21. Tarantino G, Conca P, Capone D, Gentile A, Polichetti G, Basile V. Reliability of Total Overnight Salivary Caffeine Assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. Eur J Clin Pharmacol. 2006;62(8):605-612.
22. Rubin T, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endoscop. 2003;58(3):369-373.
23. de Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(1):165-171.
24. McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Analyt Toxicol. 2003;27(7):520-522.
25. McDonagh JE, Nathan VV, Bonavia IC, Moyle GR, Tanner AR. Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function. Gut. 1991;32(6):681-684.
26. Rettie AE, Tai G. The pharmacogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006;6(4):223-227.
27. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2(3):116-127.
28. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994;3(5):413-421.
29. Miceli JN, Aravind MK, Ferrel WJ. Analysis of caffeine: comparison of the manual enzyme multiplied immunoassay (EMIT), automated EMIT, and high-performance liquid chromatography procedures. Ther Drug Monit. 1984;6(3):344-347.
30. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxantine/caffeine ratio in plasma and in saliva. *Pharmacogenetics*. 1994;4(3):109-116.

31. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. *N Engl J Med*. 1997;336(21):1506-1511.

32. Pengo V, Crippa L, Falanga A, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. *J Thromb Haemost*. 2012;10(10):1979-1987.

33. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. *Blood*. 2012;119(13):3016-3023.

34. Bourgeois S, Jorgensen A, Zhang EJ, et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort. *Genome Med*. 2016;8(1):2.

35. Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E. Influence of the genetic polymorphism in the 5’-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. *Mutat Res*. 2005;587(1-2):59-66.